- Market Capitalization, $K 3,300,086
- Shares Outstanding, K 157,522
- Annual Sales, $ 1,094 M
- Annual Income, $ -139,310 K
- 60-Month Beta 1.77
- Price/Sales 2.97
- Price/Cash Flow 33.38
- Price/Book 3.05
|Period||Period Low||Period High||Performance|
| || |
+1.25 (+6.35%)since 11/06/19
| || |
+0.69 (+3.41%)since 09/06/19
| || |
-13.82 (-39.75%)since 12/06/18
The Global Research report provides information regarding market size, share, trends, growth, cost structure, global market competition landscape, market drivers, challenges and opportunity, capacity,...
Sage Therapeutics' (SAGE) phase III study on pipeline candidate SAGE-217 for the treatment of major depressive disorder fails to meet the primary endpoint.
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.
Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.
AstraZeneca (AZN) divests commercial rights to its schizophrenia and bipolar disorder medicines Seroquel/Seroquel XR in the United States and Canada to Cheplapharm Arzneimittel GmbH.
Sangamo Therapeutics (SGMO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Epizyme (EPZM) announces that the FDA committee will review its NDA for lead candidate, tazemetostat, on Dec 18.
The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.
Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Global Blood (GBT) shares rose more than 5% in the last trading session, amid huge volumes.